FDA OKs Boxed Warning for Pfizer’s Xeljanz Following Serious Safety Concerns

Drug Industry Daily
The FDA has approved new warnings for Xeljanz and Xeljanz XR (tofacitinib), including a boxed warning. The warning of an increased risk of blood clots and death applies to the 10 mg twice daily dosage of the drug, which is approved for certain patients with ulcerative colitis.

To View This Article:


Subscribe To Drug Industry Daily